MediciNova Inc Cash Flow Conversion Efficiency
MediciNova Inc cash flow conversion efficiency. Based on the latest financial reports, MediciNova Inc (MNOV) has a cash flow conversion efficiency ratio of -0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.70 Million) by net assets ($43.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MediciNova Inc (2003–2024)
Cash flow conversion efficiency of MediciNova Inc from 2003 to 2024. This chart illustrates how MediciNova Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest MediciNova Inc stock price today for real-time trading data and today's change.
MediciNova Inc Cash Flow Conversion Ratio Explained
MediciNova Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MediciNova Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MediciNova Inc ranked by their cash flow conversion efficiency. Also see how much is MediciNova Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oncopeptides AB
ST:ONCO
|
3.676x |
|
Xchanging Solutions Limited
NSE:XCHANGING
|
0.045x |
|
Satia Industries Limited
NSE:SATIA
|
0.082x |
|
Trinity Precision Technology Co Ltd
TWO:4534
|
-0.019x |
|
ABITARE IN S.P.A.
F:1BN
|
-0.033x |
|
Simply Better Brands Corp
V:SBBC
|
-0.789x |
|
Hyundai Everdigm Corp
KQ:041440
|
-0.014x |
|
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd
KQ:307750
|
0.040x |
Annual Cash Flow Conversion Efficiency for MediciNova Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of MediciNova Inc from 2003 to 2024. Review cash generation quality of MediciNova Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.50 Million | $-10.64 Million | -0.203x | -70.16% |
| 2023-12-31 | $62.38 Million | $-7.43 Million | -0.119x | +35.19% |
| 2022-12-31 | $70.24 Million | $-12.91 Million | -0.184x | -63.95% |
| 2021-12-31 | $83.68 Million | $-9.38 Million | -0.112x | +26.13% |
| 2020-12-31 | $71.33 Million | $-10.83 Million | -0.152x | -24.58% |
| 2019-12-31 | $74.89 Million | $-9.12 Million | -0.122x | +2.27% |
| 2018-12-31 | $73.11 Million | $-9.11 Million | -0.125x | +30.42% |
| 2017-12-31 | $38.64 Million | $-6.92 Million | -0.179x | +5.48% |
| 2016-12-31 | $34.53 Million | $-6.55 Million | -0.190x | +13.19% |
| 2015-12-31 | $32.75 Million | $-7.15 Million | -0.218x | -688.65% |
| 2014-12-31 | $22.01 Million | $816.53K | 0.037x | +108.86% |
| 2013-12-31 | $25.43 Million | $-10.65 Million | -0.419x | +47.48% |
| 2012-12-31 | $14.88 Million | $-11.86 Million | -0.797x | -40.78% |
| 2011-12-31 | $23.50 Million | $-13.31 Million | -0.566x | +20.94% |
| 2010-12-31 | $24.70 Million | $-17.70 Million | -0.716x | -68.48% |
| 2009-12-31 | $40.01 Million | $-17.01 Million | -0.425x | +3.26% |
| 2008-12-31 | $48.04 Million | $-21.12 Million | -0.440x | +33.24% |
| 2007-12-31 | $66.61 Million | $-43.86 Million | -0.658x | -95.22% |
| 2006-12-31 | $100.98 Million | $-34.06 Million | -0.337x | -100.04% |
| 2005-12-31 | $135.71 Million | $-22.88 Million | -0.169x | +90.45% |
| 2004-12-31 | $7.67 Million | $-13.55 Million | -1.766x | -36.09% |
| 2003-12-31 | $4.57 Million | $-5.93 Million | -1.298x | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more